Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy

Diabet Med. 2015 Feb;32(2):267-73. doi: 10.1111/dme.12590. Epub 2014 Oct 17.

Abstract

Aims: To assess markers of inflammation and bone turnover at presentation and at resolution of Charcot osteoarthropathy.

Methods: We measured serum inflammatory and bone turnover markers in a cross-sectional study of 35 people with Charcot osteoarthropathy, together with 34 people with diabetes and 12 people without diabetes. In addition, a prospective study of the subjects with Charcot osteoarthropathy was conducted until clinical resolution.

Results: At presentation, C-reactive protein (P = 0.007), tumour necrosis factor-α (P = 0.010) and interleukin-6 (P = 0.002), but not interleukin-1β, (P = 0.254) were significantly higher in people with Charcot osteoarthropathy than in people with and without diabetes. Serum C-terminal telopeptide (P = 0.004), bone alkaline phosphatase (P = 0.006) and osteoprotegerin (P < 0.001), but not tartrate-resistant acid phosphatase (P = 0.126) and soluble receptor activator of nuclear factor-κβ ligand (P = 0.915), were significantly higher in people with Charcot osteoarthropathy than in people with and without diabetes. At follow-up it was found that tumour necrosis factor-α (P = 0.012) and interleukin-6 (P = 0.003), but not C-reactive protein (P = 0.101), interleukin-1β (P = 0.457), C-terminal telopeptide (P = 0.743), bone alkaline phosphatase (P = 0.193), tartrate-resistant acid phosphatase (P = 0.856), osteoprotegerin (P = 0.372) or soluble receptor activator of nuclear factor-kβ ligand (P = 0.889), had significantly decreased between presentation and the 3 months of casting therapy time point, and all analytes remained unchanged from 3 months of casting therapy until resolution. In people with Charcot osteoarthropathy, there was a positive correlation between interleukin-6 and C-terminal telopeptide (P = 0.028) and tumour necrosis factor-α and C-terminal telopeptide (P = 0.013) only at presentation.

Conclusions: At the onset of acute Charcot foot, serum concentrations of tumour necrosis factor-α and interleukin-6 were elevated; however, there was a significant reduction in these markers at resolution and these markers may be useful in the assessment of disease activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Arthropathy, Neurogenic / blood
  • Arthropathy, Neurogenic / complications
  • Arthropathy, Neurogenic / physiopathology
  • Arthropathy, Neurogenic / therapy*
  • Biomarkers / blood
  • Bone Resorption / etiology
  • Bone Resorption / prevention & control*
  • Cohort Studies
  • Collagen Type I / blood*
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetes Mellitus, Type 2 / complications*
  • Down-Regulation*
  • Humans
  • Immobilization
  • Inflammation Mediators / blood
  • Interleukin-6 / blood*
  • Longitudinal Studies
  • Middle Aged
  • Peptides / blood*
  • Prospective Studies
  • Remission Induction
  • Up-Regulation

Substances

  • Biomarkers
  • Collagen Type I
  • IL6 protein, human
  • Inflammation Mediators
  • Interleukin-6
  • Peptides
  • collagen type I trimeric cross-linked peptide